Last reviewed · How we verify
NCT06900426
Lung Atelectasis Improvement Through Positive End Expiratory Pressure During Anesthetic Induction
NA trial testing 10 PEEP in Lung Injury, Acute in 120 participants. Completed in 28 April 2025.
28 April 2025
Quick facts
| Lead sponsor | Fudan University |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | prevention |
| Enrollment | 120 |
| Start date | 28 March 2025 |
| Primary completion | 28 April 2025 |
| Estimated completion | 28 April 2025 |
| Sites | 1 location across China |
Drugs / interventions tested
- 10 PEEP
- ZEEP
- 5PEEP
Conditions studied
- Lung Injury, Acute — all drugs for Lung Injury, Acute →
Sponsor
Fudan University
Who can join
Adults 18 to 80, any sex, with Lung Injury, Acute. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Anesthetic induction could lead to lung atelectasis, increase intrapulmonary shunt, and potentially impair oxygenation. The study aimed to validate that a positive end-expiratory pressure (PEEP) of 10 cmH2O could reduce lung atelectasis, comparing to 0 or 5 cmH2O with limited overdistension.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Applying positive end-expiratory pressure to facemask ventilation improves post-induction lung atelectasis: a three-arm randomized controlled trial.
Yang L, Wu L, Ye J, Zhao Z, et al · · 2025 · PMID 41107724 · DOI 10.1186/s12871-025-03352-z
Verify or expand the search:
- PubMed search for NCT06900426
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Lung Injury, Acute
Currently open trials in the same condition.
- NCT04289324 — Open Lung Maneuvers During High Frequency Oscillatory Ventilation in Preterm Infants · NA · recruiting
Other Fudan University trials
Trials by the same sponsor.
- NCT06196671 — Oncolytic Virus Plus PD-1 Inhibitor to Patients With Advanced Pancreatic Cancer · Phase 2 · not yet recruiting
- NCT07423611 — ctDNA-Guided Chemotherapy Omission With Ribociclib Plus Endocrine Therapy in HR-Positive/HER2-Negative Breast Cancer · Phase 2 · not yet recruiting
- NCT07410559 — Neoadjuvant Imlunestrant Plus Abemaciclib Treatment Guided by Ki67 Index After 2 Weeks for ER-Positive HER2-Negative Bre · Phase 2 · not yet recruiting
- NCT07490119 — Becotatug Vedotin Combined With Cetuximab in the Later-line Treatment of Metastatic RAS Wild-type Colorectal Cancer · Phase 2 · not yet recruiting
- NCT07497919 — A Study of Becotatug Vedotin Combined With Pucotenlimab in the Treatment of EGFR-Positive Advanced Penile Cancer · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06900426 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Fudan University
- Last refreshed: 29 May 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06900426.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing